Stemedica announced today that Richard Mejia, Jr. has joined the Company’s Board of Directors and will be Chairman of the Company’s Audit Committee effective January 31, 2014.
Mr. Mejia spent 38 years with Ernst & Young, LLP where he was a partner for 25 years. He spent the last eight years exclusively serving life science companies and as a Life Science Industry leader for his firm. Mr. Mejia has extensive experience in securities filings and offerings and other strategic transactions. “Rich’s extensive experience as a leader in the life sciences practice at Ernst & Young provides Stemedica with the kind of seasoned leadership we are pursuing,” stated Roger Howe, PhD, Stemedica’s Executive Chairman. Mr. Mejia is also an experienced director and Audit Committee member for both healthcare and technology companies.
About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies, Inc. is a specialty biopharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for clinical trials in ischemic stroke, cutaneous photoaging and acute myocardial infarction. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The company is headquartered in San Diego, California.
Media Contact for Stemedica: Dave McGuigan at email@example.com